TPL108390 : Randomised, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

Trial Profile

TPL108390 : Randomised, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Eltrombopag (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C; Thrombocytopenia
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ENABLE-2
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2013 Results from this trial supported the approval of a marketing authorisation application for eltrombopag with the European Commission for treating chronic hepatitis C-associated thrombocytopenia according to a GlaxoSmithKline media release.
    • 06 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top